CAR T-Cell Therapy Offers Hope for Highly Sensitized Patients

Key Summary

• • Researchers at the University of Pennsylvania successfully used CAR T-cell therapy to reduce harmful antibodies in highly sensitized kidney transplant candidates.
  • Two patients with end-stage kidney disease and near-100% cPRA scores became eligible for kidney transplantation after treatment.
  • Both patients received successful kidney transplants without signs of organ rejection or antibody rebound.
  • The Phase I trial demonstrated favorable safety, with no severe cytokine release syndrome or neurotoxicity observed.
  • The approach may offer a new pathway to transplantation for thousands of patients who struggle to find compatible donor kidneys.
  • For more updates, explore all Nephrology CME Conferences & Online Courses

CAR T-Cell Therapy Enables Kidney Transplants for Highly Sensitized Patients

For thousands of patients with end-stage kidney disease, finding a compatible donor kidney remains one of the greatest challenges in transplantation medicine. A groundbreaking clinical trial led by researchers at the University of Pennsylvania has now demonstrated that CAR T-cell therapy may help overcome this barrier by reducing the harmful antibodies that prevent successful kidney transplantation.

How CAR T-Cell Therapy Helped Make Kidney Transplantation Possible

Kidney transplantation remains the preferred treatment for many patients with kidney failure. However, highly sensitized patients develop immune antibodies that can attack donor organs, making compatible matches extremely rare. These patients often have a Calculated Panel Reactive Antibody (cPRA) score of 99.9% or higher, leaving them compatible with fewer than one in 1,000 donor kidneys.

In a pioneering Phase I clinical trial, researchers adapted CAR T-cell therapy, originally developed for blood cancer treatment, to target the immune cells responsible for producing these harmful antibodies. The investigational approach combined CD19-targeted CAR T cells, which eliminate memory B cells, with BCMA-targeted CAR T cells that remove antibody-producing plasma cells.

This dual-cell therapy strategy significantly reduced circulating antibodies and effectively reset key components of the immune system. As a result, two highly sensitized patients who had spent years on transplant waiting lists became eligible for donor kidneys and successfully underwent kidney transplantation.

What Did the Clinical Trial Show?

The study involved two patients whose cPRA scores were close to 100%, making donor compatibility nearly impossible. Following CAR T-cell treatment, both experienced substantial reductions in donor-reactive antibodies.

The lowered antibody burden expanded their donor options and ultimately led to successful kidney transplants. Importantly, researchers reported no evidence of donor-specific antibody rebound or organ rejection after transplantation.

Safety findings were equally encouraging. Neither patient developed severe cytokine release syndrome nor neurotoxicity, complications sometimes associated with CAR T-cell therapies in oncology settings. Researchers also observed a gradual recovery of healthy B-cell populations, indicating that immune depletion was temporary.

Could CAR T-Cell Therapy Change the Future of Transplant Medicine?

One of the study participants, Andrew Boyd, had lived with kidney disease for more than four decades and had previously received two kidney transplants. After years of unsuccessful waiting for a third compatible donor, CAR T-cell therapy lowered his antibody levels sufficiently to allow transplantation in 2025.

The findings suggest that cellular immunotherapy may offer a new treatment pathway for highly sensitized transplant candidates who have exhausted conventional desensitization options such as plasma exchange and antibody-blocking medications.

Researchers from Penn Medicine, NYU Langone, and Massachusetts General Hospital will continue evaluating higher CAR T-cell doses and larger patient populations in future trial phases. If confirmed in broader studies, this strategy could expand transplant access for thousands of patients who currently face limited opportunities for kidney transplantation.

Explore all Nephrology CME Conferences & Online Courses

For nephrologists, transplant surgeons, immunologists, and transplant nurses, these early results highlight the growing role of cellular therapies beyond oncology and their potential to address longstanding barriers in organ transplantation.

Source:

University of Pennsylvania School of Medicine